Search research articles
Contact Us
Filters
Showing results (201-210 of 221) with videos related to
Page
of 23
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2006
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group
Kaci L Osenga, Jacquelyn A Hank, Mark R Albertini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 5, 2008
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel
Keith T Flaherty, Joan Schiller, Lynn M Schuchter, et al.
Cell Reports
|
December 14, 2023
NK cells propagate T cell immunity following in situ tumor vaccination
Won Jong Jin, Justin C Jagodinsky, Jessica M Vera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2020
Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
Richard K Yang, Igor B Kuznetsov, Erik A Ranheim, et al.
Cancer Immunology, Immunotherapy : CII
|
August 4, 2018
Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma
Mark R Albertini, Richard K Yang, Erik A Ranheim, et al.
Plos One
|
August 12, 2021
Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting
Kara Magee, Ian R Marsh, Michelle M Turek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2010
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study
Suzanne Shusterman, Wendy B London, Stephen D Gillies, et al.
Allergy
|
May 8, 2013
Airborne olive pollen counts are not representative of exposure to the major olive allergen Ole e 1
C Galan, C Antunes, R Brandao, et al.
Journal for Immunotherapy of Cancer
|
May 8, 2021
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
Ahmad A Tarhini, Ni Kang, Sandra J Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2017
Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697)
Sanjiv S Agarwala, Sandra J Lee, Waiki Yip, et al.
Page
of 23
Search research articles
Search
Showing results (201-210 of 221) with videos related to
Sort By:
Page
of 23
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2006
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group
Kaci L Osenga, Jacquelyn A Hank, Mark R Albertini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 5, 2008
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel
Keith T Flaherty, Joan Schiller, Lynn M Schuchter, et al.
Cell Reports
|
December 14, 2023
NK cells propagate T cell immunity following in situ tumor vaccination
Won Jong Jin, Justin C Jagodinsky, Jessica M Vera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2020
Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
Richard K Yang, Igor B Kuznetsov, Erik A Ranheim, et al.
Cancer Immunology, Immunotherapy : CII
|
August 4, 2018
Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma
Mark R Albertini, Richard K Yang, Erik A Ranheim, et al.
Plos One
|
August 12, 2021
Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting
Kara Magee, Ian R Marsh, Michelle M Turek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2010
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study
Suzanne Shusterman, Wendy B London, Stephen D Gillies, et al.
Allergy
|
May 8, 2013
Airborne olive pollen counts are not representative of exposure to the major olive allergen Ole e 1
C Galan, C Antunes, R Brandao, et al.
Journal for Immunotherapy of Cancer
|
May 8, 2021
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
Ahmad A Tarhini, Ni Kang, Sandra J Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2017
Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697)
Sanjiv S Agarwala, Sandra J Lee, Waiki Yip, et al.
Page
of 23